Literature DB >> 32688199

Structure-activity relationships of Wee1 inhibitors: A review.

Xingkai Du1, Jian Li2, Xiaojiao Luo1, Rong Li3, Feng Li3, Yiwen Zhang4, Jianyou Shi5, Jun He6.   

Abstract

Wee1 kinase plays an important role in regulating G2/M checkpoint and S phase, and the inhibition of it will lead to mitotic catastrophe in cancer cells with p53 mutation or deletion. Therefore, the mechanism of Wee1 kinase in cancer treatment and the development of its inhibitors have become a research hotspot. However, although a variety of Wee1 inhibitors with different scaffolds and considerable activity have been successfully identified, so far no one has systematically summarized the structure-activity relationships (SARs) of Wee1 inhibitors. Previous reviews mainly focused on its mechanism and clinical application. To facilitate the rational design and development of Wee1 inhibitors in the future, this paper systematically summarizes its structural types, SARs and binding modes according to the Wee1 inhibitors reported in scientific journals, and also summarizes the regulatory effect of Wee1 kinase on cell cycle and the progress of its inhibitors in clinical application.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Cell cycle checkpoint; Structure-activity relationships; Wee1 inhibitors

Mesh:

Substances:

Year:  2020        PMID: 32688199     DOI: 10.1016/j.ejmech.2020.112524

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  Modulation of KRAS Mutant by Inhibiting PLK1 Kinase in Cancer Therapeutics.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-09-15       Impact factor: 4.632

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.